valu usd unless otherwis note
post-cal up guid still beatabl
view rapid us pnh ultomiri switch give us comfort
franchis defens vs competition/biosimilar see soliri
rapid acceler gmg drive franchis beat vs guidanc
throughout focu ultomiri switch germani
japan go mid-year well soliri nmo data
pt reduct result reduc cash follow string bd activ
revenu guidanc rais inclus soliri headwind
continu see beat/rais potenti continu see soliri
ultomiri guidanc conserv link
first-blush note mid-rang guidanc impli minim
q/q growth remaind though note guidanc
includ headwind russia elizaria recent approv
russian soliri biosimilar well continu price headwind brazil
turkey soliri miss bullish estim vs
prior est larg result faster ultomiri switch vs
estim vs prior est see continu focu
complement franchis biosimilar competit heard
link note though increas focu
approach focu shift germany/japanes ultomiri pnh launch/
switch soliri gmg launch territori present
prevent trial soliri nmo link take prevent
posit top-lin data focu relaps prevent key
physician concern/pati diseas pt reduct stem
decreas ye estim cash level follow string
elizaria biosim risk gate within russia limit impact
estim russia soliri sale anticip
compet elizaria price discount vs soliri moscow-bas
elizaria russia treatment pnh ahu
minor portion soliri sale calcul
usd total sale russia anticip soliri
abl compet elizaria price discount per pack
vs soliri russian market limit impact
note russian soliri alreadi enjoy price discount
vs western countri addit anticip elizaria limit
russia near-term futur given extens intellectu
properti geographi well extens differ biosimilar
regulatori barrier russian european japanes us market
addit russian biosimilar biocad schedul complet
bioequival studi elizaria jointli develop swiss/
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
bloomberg capit market estim upside/downside/target
price target base sum-of-the-part
sotp methodolog estim probability-adjust
npv follow soliri sale pnh soliri
sale ahu strensiq sale
share kanuma sale lal-d soliri sale
mg soliri sale nmo
ultomiri sale pnh ultomiri
sale ahu ultomiri
sale neuro sale wilson diseas
compani debt posit price
target support outperform rate
upsid scenario assum
approv wilson diseas po
approv mg waiha po
consensu ultomiri switch biosimilar competit
soliri appear europ increas soliri sale
downsid scenario assum assum
discount soliri npv base earlier-than-
anticip biosimilar entri solri indic
despit pnh patient competit like soliri
mg approv see declin soliri pnh sale
larg off-set expans ahu mg focu
long-term revenu expens guidanc amid intens
development competit field complement
inhibitor anticip restructur could help remov
near-term overhang stock follow manag
could help protect pnh ahu
market competitor see dose
regimen promis highli conveni though riski
development strategi present pk
dose use remain unclear
whether recycl strategi use extend half
life hold high concentr note
therapeut antibodi commerci
high dose though conced dose would
like seen conveni mani competitor
ip extens like fend soliri biosimilar
see recent composit matter formul
method use patent extend ip us
hold launch biosimilar anticip issuanc
similar patent eu extend protect
eu countri view biosimilar soliri near-term
upcom potenti catalyst soliri nmosd data
soliri nmosd pdufa june
ultomiri eu approv pnh launch pnh
approv soliri nmosd initi
phase studi nmosd
risk factor neg influenc valuat
rate includ develop setback includ
pnh posit develop
progress competitor complement program
clinic updat slightli push back clinic develop plan
formerli syntimmun acquisit plan initi adapt ph
registr studi waiha gmg around vs prior plan data
follow initi trial waiha gmg setback result
prior clinic suppli post-acquisit
subsequ correct manufactur disrupt clinic product suppli
howev note transit toward adapt trial design mitig delay
potenti registr timelin disrupt clinic suppli frustrat
encourag earli discoveri correct impur
upcom catalyst may american academi neurolog soliri nmosd
rarx soliri competitor zilucoplan phase data gmg link planner
soliri nmosd pdufa june initi proof concept poc studi
ultomiri ppm al data fcrn portfolio earli
first-in-human studi eu launch germani ultomiri pnh
model chang updat model report made adjust
product revenu expens assumpt current trend updat
guidanc increas ultomiri sale estim vs earlier
account impress switch rate pnh patient soliri led
concomit declin soliri estim given patient cannib
addit adjust rest-of-world row soliri estim price headwind
russian biosimilar elizaria expens estim increas vs
prior management increas guidanc vs earlier
addit updat model reflect pay revolv
credit facil modif long-term debt repay schedul
recent adjust cash forecast follow recent string acquisit
activ see note result decreas pt
compani report capit market estim
chang model revenu expens expens expens incom incom expens incom incom non- non- exhibit incom statement
compani report capit market estim
incom statement mm fy soliri net ultomiri sale risk adjust net complement net strensiq net kanuma net sale risk adjust net metabol net revenues- sale mg- sale waiha- net product contract research revenues- total gross sg total oper gaap oper incom loss incom gaap net incom gaap incom tax net incom gaap basic ep dilut net incom non-gaap dilut dilut exhibit sotp valuat
compani report capit market estim
soliri pnh ahu lal-d mg nmo pnh ahu mg nmo al ppm valu sum-of-the-part valuat exhibit price target breakdown
compani report capit market estim
price target base sum-of-the-part sotp methodolog
estim probability-adjust npv follow soliri sale pnh soliri
sale ahu strensiq sale kanuma sale lal-d
soliri sale mg soliri sale nmo ultomiri
sale pnh ultomiri sale ahu ultomiri
sale neuro sale wilson diseas
sale cash compani debt posit
share price target support outperform rate
risk rate price target
factor neg influenc valuat rate includ develop
set-back includ neg readout studi ahu posit develop
progress competitor complement program
alexion pharmaceut global fulli integr biopharmaceut compani
focus treatment rare diseas lead commerci product soliri eculizumab
human monoclon antibodi direct complement factor soliri approv
treatment paroxysm nocturn hemoglobinuria pnh atyp hemolyt urem
syndrom ahu gener myasthenia gravi three ultra-rar diseas caus
uncontrol complement activ alexion aim expand soliri neurolog
transplant disord conduct late-stag develop program neuromyel optica
nmo delay graft function dgf antibody-medi reject amr
alexion also market strensiq asfotas alfa enzym replac therapi ert indic
hypophosphatasia grant us approv octob eu approv
septemb approv japan juli addit
acquisit synageva alexion own kanuma sebelipas alfa ert treatment
lysosom acid lipas defici lal-d receiv eu us market approv
septemb decemb respect approv japan march
compani current develop next gener complement inhibitor
treatment pnh ahu potenti complement associ diseas
